IVMED 85
Alternative Names: IVMED-85Latest Information Update: 28 Nov 2023
Price :
$50 *
At a glance
- Originator iVeena Delivery Systems
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Degenerative myopia
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Degenerative myopia in USA (Ophthalmic, Drops)
- 26 Oct 2023 iVeena Delivery Systems plans a first-in-human clinical trial for Degenerative myopia (Ophthalmic, Drops) in 2024
- 07 Mar 2023 iVeena Delivery Systems plans a phase I/II trial for Myopia (In children, In adolescents) (Ophthalmic) in May 2023 (NCT05761795)